OncoMatch/Clinical Trials/NCT06345365
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Is NCT06345365 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including mitoxantrone liposome, Ara-Cytarabine and azacitidine and Daunorubicin,Ara-Cytarabine, azacitidine for acute myeloid leukaemia.
Treatment: mitoxantrone liposome, Ara-Cytarabine and azacitidine · Daunorubicin,Ara-Cytarabine, azacitidine — Investigator proposed to apply the new dosage form of mitoxantrone hydrochloride liposomes to the clinical treatment of AML, while combining with cytarabine and azacitidine to form the MA+AZA treatment regimen(Mitoxantrone liposome +Ara-Cytarabine+Azacitidine), which would provide an optimal induction treatment regimen for patients with primary AML by comparing with the traditional chemotherapy regimen, DA+AZA (Daunorubicin+Ara-Cytarabine+Azacitidine).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Kidney function
serum creatinine <1.5 × uln, 80 ml/min ≤ creatinine clearance ≤120 ml/min
Liver function
serum total bilirubin ≤1.5 × uln, ast/alt <2 × uln
Cardiac function
ejection fraction ef ≥50%, ultrasensitive troponin and natriuretic peptide <1.5 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06345365 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages